drugset
drugset / Trial / NCT03891108

A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants

NCT03891108 ↗

Phase 1 Completed 60 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

Main Objective of this study is to compare the single intravenous (IV) infusion pharmacokinetics (PK) of BMS-986231 and its metabolites (BMT-284730, BMT-279554, and CAR-000463) following of up to 2 test formulations of BMS-986231 relative to the reference formulation.

Timeline

Start
2019-02-28
Primary completion
2019-07-29
Completion
2019-07-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator cimlanod Other / unclassified — Intravenous

Indications

heart failure